Turkey's biosimilar sector is emerging as one of the most closely watched segments within the country's pharmaceutical industry, supported by rising healthcare expenditure, an expanding base of patients requiring biologic therapies, and strong government emphasis on reducing the cost burden of complex medicines. Turkey biosimilar market size reached USD 422.0 Million in 2025. The market is projected to reach USD 2,711.7 Million by 2034, exhibiting a growth rate (CAGR) of 22.27% during 2026-2034. As patents on major biologic drugs continue to expire and Turkey's healthcare system seeks more affordable treatment alternatives, biosimilars are increasingly positioned as a critical lever for expanding patient access to advanced therapies across oncology, autoimmune, and chronic disease categories.

How AI is Reshaping the Future of Turkey Biosimilar Market?

·         AI-Driven Drug Development: Pharmaceutical companies operating in Turkey are increasingly applying machine learning models to accelerate biosimilar development timelines, particularly in protein characterization and analytical similarity testing required for regulatory approval.

·         Predictive Pharmacovigilance: AI-powered monitoring systems are helping manufacturers and health authorities track adverse event patterns more efficiently, supporting faster safety signal detection across biosimilar product lines.

·         Manufacturing Process Optimization: Machine learning algorithms are being deployed in bioreactor monitoring and quality control, helping manufacturers maintain batch-to-batch consistency, a critical requirement for biosimilar regulatory compliance.

·         AI-Enabled Market Access Analytics: Companies are using predictive analytics to identify prescribing patterns and forecast demand across public and private healthcare channels, improving supply chain planning for biosimilar rollouts.

·         Digital Health Integration: AI-supported electronic health record systems are helping physicians identify patients eligible for biosimilar switching, supporting broader adoption across Turkey's public healthcare network.

Grab a sample PDF of this report: https://www.imarcgroup.com/turkey-biosimilar-market/requestsample

Turkey Biosimilar Market Trends & Drivers

1. Growing Demand for Cost-Effective Biologic Therapies

Rising demand for cost-effective biologic therapies is a major growth driver for the Turkey Biosimilar Market, particularly among hospitals, pharmaceutical distributors, healthcare procurement organizations, and manufacturers. Biosimilars can improve access to high-value treatments while helping healthcare systems manage spending on biologic medicines. Demand is particularly relevant in oncology and autoimmune care, where biologic therapies represent significant treatment costs and ongoing clinical demand. Turkey’s biosimilar drug market grew strongly in 2024, while industry data shows biosimilars substantially outpaced broader pharmaceutical and biotechnology market growth over the 2015–2024 period. For B2B companies, this creates opportunities to expand portfolios, strengthen hospital supply agreements, develop competitive pricing strategies, and invest in manufacturing capabilities that can support broader adoption across Turkey’s healthcare ecosystem.

2. Supportive Regulatory and Reimbursement Environment

Government healthcare policies, reimbursement mechanisms, and improving regulatory clarity are supporting expansion in the Turkey Biosimilar Market. Turkey’s pharmaceutical system combines centralized reimbursement through the Social Security Institution with regulatory oversight by the Turkish Medicines and Medical Devices Agency, making market access and reimbursement important commercial considerations for manufacturers and distributors. Recent updates to Turkey’s biosimilar guideline have provided greater clarity around comparability, data requirements, and manufacturing expectations, helping create a more predictable environment for developers. For B2B stakeholders, clearer regulatory pathways can reduce uncertainty around product development, registration, commercialization, and investment decisions. Companies that closely monitor reimbursement requirements, pricing policies, regulatory changes, and procurement processes can position their biosimilar portfolios more effectively and improve access to institutional healthcare channels.

3. Expansion of Local Manufacturing and R&D Capabilities

Expansion of local pharmaceutical manufacturing, R&D, clinical collaboration, and technology capabilities is another important growth driver for the Turkey Biosimilar Market. Turkey has an established pharmaceutical manufacturing base, with numerous production facilities and a growing focus on biotechnology and advanced medicines. Industry data indicates that several biosimilar products are already manufactured domestically, creating opportunities for technology providers, contract manufacturers, research organizations, distributors, and pharmaceutical companies to participate across the value chain. Increased investment in specialized production and development capabilities can support product availability, supply resilience, and potential export opportunities. For B2B audiences, partnerships between local manufacturers, multinational pharmaceutical companies, research institutions, and healthcare organizations can accelerate commercialization while strengthening technical expertise, production capacity, and competitive positioning in Turkey and neighboring regional markets.

Turkey Biosimilar Industry Segmentation

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Turkey biosimilar market share. It includes detailed coverage across the following segments.

The report has segmented the market into the following categories:

Product Type Insights:

• Monoclonal Antibodies
• Recombinant Human Insulin
• Recombinant Growth Hormone
• Erythropoietin
• Interferon
• Others

Application Insights:

• Oncology
• Autoimmune Diseases
• Blood Disorders
• Growth Hormone Deficiency
• Chronic and Other Conditions

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Insights:

• Istanbul
• Ankara
• Izmir
• Bursa
• Others

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players operating in Turkey's biosimilar manufacturing and distribution sector.

Recent News and Developments in Turkey Biosimilar Market

·         February 2024: A leading Turkish pharmaceutical manufacturer announced the expansion of its biologics production facility in Istanbul, aimed at increasing domestic capacity for monoclonal antibody biosimilars.

·         September 2024: Turkey's Social Security Institution updated its reimbursement guidelines to further encourage biosimilar substitution across select oncology and autoimmune treatment categories within public hospitals.

·         May 2025: A Turkish biopharmaceutical company entered into a licensing agreement with a European biosimilar developer to co-produce insulin biosimilars for both domestic distribution and regional export.

·         January 2026: The Turkish Medicines and Medical Devices Agency introduced updated regulatory guidance aligning local biosimilar approval pathways more closely with international analytical similarity standards, aimed at streamlining market entry for new products.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302